Rheumatology, Osteoarthritis
7. May 2021
Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study
ABSTRACT
Objective: The FORWARD (FGF-18 Osteoarthritis Randomized Trial with Administration of Repeated Doses) trial assessed efficacy and safety of the potential disease-modifying osteoarthritis drug (DMOAD) sprifermin in patients with knee osteoarthritis. Here, we report 5-year efficacy and safet…
Read the publication
Journal:
Authors:
- Eckstein F,
- Hochberg MC,
- Guehring H,
- Moreau F,
- Ona V,
- Bihlet AR,
- Byrjalsen I,
- Andersen JR,
- Daelken B,
- Guenther O,
- Ladel C,
- Michaelis M,
- Conaghan PG,